Metropolitan Life Insurance Co NY Purchases 221 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Metropolitan Life Insurance Co NY grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,557 shares of the biopharmaceutical company’s stock after buying an additional 221 shares during the period. Metropolitan Life Insurance Co NY’s holdings in Alnylam Pharmaceuticals were worth $612,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Meeder Asset Management Inc. increased its stake in Alnylam Pharmaceuticals by 332.9% during the 1st quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 263 shares during the period. Quadrant Capital Group LLC increased its stake in Alnylam Pharmaceuticals by 543.2% during the 1st quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 440 shares during the period. Flagship Harbor Advisors LLC bought a new position in Alnylam Pharmaceuticals during the 1st quarter worth $47,000. Resources Investment Advisors Inc. bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth $58,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Alnylam Pharmaceuticals by 268.9% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 701 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 511 shares during the period. 89.78% of the stock is owned by institutional investors.

A number of research firms have commented on ALNY. Cantor Fitzgerald restated a “hold” rating and set a $58.00 price objective on shares of Eagle Pharmaceuticals in a research note on Monday, April 15th. BidaskClub lowered Xencor from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 11th. Leerink Swann lifted their price target on Alnylam Pharmaceuticals to $90.00 and gave the company a “market perform” rating in a research note on Tuesday, April 9th. Zacks Investment Research lowered Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Finally, Svb Leerink decreased their price target on Zogenix from $60.00 to $48.00 and set an “outperform” rating on the stock in a research note on Tuesday, April 9th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $127.44.

In related news, CEO John Maraganore sold 49,457 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $70.00, for a total transaction of $3,461,990.00. Following the sale, the chief executive officer now owns 239,450 shares in the company, valued at approximately $16,761,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.60% of the company’s stock.

ALNY stock traded down $0.52 during midday trading on Friday, reaching $75.37. 1,334,910 shares of the stock were exchanged, compared to its average volume of 610,965. The company has a market cap of $8.09 billion, a PE ratio of -9.96 and a beta of 2.50. Alnylam Pharmaceuticals, Inc. has a 52 week low of $60.27 and a 52 week high of $124.21. The company has a quick ratio of 9.12, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. The firm has a fifty day moving average of $71.66.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.20) by $0.47. The business had revenue of $33.29 million for the quarter, compared to analyst estimates of $21.60 million. Alnylam Pharmaceuticals had a negative return on equity of 55.33% and a negative net margin of 929.51%. Alnylam Pharmaceuticals’s quarterly revenue was up 52.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.22) EPS. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -8.45 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

See Also: Leveraged Buyout (LBO) Explained

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.